and the nuclear factor of activated T cells (NFAT) family of transcription factors are critical in vascular smooth muscle cell (SMC) development and pathology. Here, we used a genomics approach to identify and validate NFAT gene targets activated during platelet-derived growth factor-BB (PDGF-BB)-induced SMC phenotypic modulation. Methods and Results-Genome-wide expression arrays were used to identify genes both (1) differentially activated in response to PDGF-BB and (2) whose differential expression was reduced by both the Cn inhibitor cyclosporin A and the NFAT inhibitor A-285222. The 20 most pharmacologically sensitive genes were validated by quantitative reverse transcription-polymerase chain reaction analysis of PDGF-BB-stimulated SMCs in the presence of Cn/NFAT inhibitors, including the VIVIT peptide. In all experiments, protein C receptor (PROCR) gene activation was reduced. We showed that PROCR expression was virtually absent in untreated, quiescent SMCs. PDGF-BB stimulation, however, induced significant PROCR promoter activation and downstream protein expression in a Cn/NFAT-dependent manner. Mutation of a species-conserved, NFAT binding motif significantly attenuated PDGF-BB-induced PROCR promoter activity, thereby distinguishing NFAT as the first PROCR transcriptional activator to date. Moreover, SMC PROCR expression was upregulated in the neointima as early as 7 days following acute vascular injury in rat carotid arteries. Conclusion-We hereby report PROCR as a novel, NFAT-dependent gene that may be implicated in vascular restenosis and consequent inward remodeling. (Arterioscler Thromb Vasc Biol. 2011;31:2665-2675.)
V ascular smooth muscle cells (SMCs) can undergo phenotypic modulation, 1 a process by which a quiescent, contractile SMC alters its expression profile to facilitate cell proliferation, migration, or inflammatory cell recruitment (see reviews 1, 2 ) . SMC phenotypic modulation is a critical event underlying atherosclerosis and in-stent restenosis that involves several signaling cascades, such as the calcineurin (Cn)/nuclear factor of activated T cells (NFAT) pathway. Cn, a cytosolic, calcium-dependent phosphatase, activates the NFAT family of transcription factors (NFATc1-c4) for nuclear translocation and subsequent target gene transcription. Cn/ NFAT activity contributes to vascular SMC proliferation and migration in response to receptor tyrosine kinase and G-protein-coupled receptor agonists, respectively. 3, 4 In vivo, Cn expression increases in response to acute vascular injury (Supplemental Figure I , available online at http://atvb.ahajournals.org), and pharmacological inhibition of Cn/NFAT signaling has been shown to significantly reduce neointima formation. 5 Identifying downstream targets of NFAT activity is therefore important in understanding the role of Cn/NFAT signaling in SMC phenotypic modulation and vascular disease.
Several NFAT target genes, although limited in number, have already been described in vascular SMCs. Many of these genes encode proteins associated with SMC proliferation, migration, and inflammation. For example, basal expression of the proinflammatory protein protease-activated receptor 1 (PAR-1) is transcriptionally regulated by NFATc1 in human saphenous vein SMCs. 6 Knockdown of endogenous NFATc1 also inhibits thrombin-induced interleukin-6 expression, supporting previous findings that interleukin-6 is an NFAT target gene. 7 Nilsson-Berglund et al showed that glucose-induced osteopontin expression in intact arteries is reduced with pharmacological inhibitors of Cn/NFAT signaling and in NFATc3 Ϫ/Ϫ mice. 8 NFATc3 occupancy at the osteopontin promoter was also demonstrated using chromatin immunoprecipitation assays. Proteins involved in cell cycling have also been identified as NFAT dependent. In human aortic SMCs, platelet-derived growth factor BB (PDGF-BB)-mediated induction of cyclin D1 was attenuated by inhibitors of Cn/NFAT signaling. Chromatin immunoprecipitation assay using an antibody to NFATc1 also showed enrichment at the cyclin D1 promoter. 9 The closely related protein cyclin A has also been reported by the same group to be NFATc1 dependent. 10 Furthermore, we and others have shown that genes upregulated with vascular injury, namely cyclooxygenase-2 and vascular cell adhesion molecule-1, exhibit Cn/ NFAT dependence, [11] [12] [13] supporting the notion that Cn/NFAT signaling is implicated in vascular remodeling.
To expand our understanding of NFAT activity in vascular SMCs, we previously applied an unbiased integrative genomics approach. 13 Putative target genes were identified using gene expression array datasets in combination with an in silico NFATome (a species-conserved list of gene promoters containing at least 1 NFAT binding site). We identified Down syndrome candidate region 1 (DSCR1) as a novel, Cn/NFATdependent, injury-responsive gene in vascular SMCs. 13 We are still, however, far from understanding the coordinated orchestration of NFAT target gene activation in vascular SMCs.
In this study, we expanded our genomics investigation to further identify NFAT target genes involved in SMC phenotypic modulation. We present 2 additional gene expression arrays where different Cn/NFAT inhibitors, cyclosporin A (CsA) 7 and A-285222, 12, 14 were each used to block NFAT activation during PDGF-BB treatment. Here, we report protein C receptor (PROCR) as a novel, Cn/NFAT-dependent gene in vascular SMCs. To our knowledge, NFATc is the first transcription factor that has been validated to transcriptionally regulate PROCR in any cell type. Furthermore, although basal medial PROCR expression in vivo was barely detectable, acute vascular injury resulted in pronounced neointimal PROCR expression. Our findings, together with the recent identification of functional PROCR in vascular SMCs, 15 suggest that PROCR may facilitate SMC phenotypic modulation and contribute to the pathological events following vascular remodeling.
Materials and Methods

Cell Culture
Rat aortic SMCs (RASMCs) were plated in base media containing 10% fetal bovine serum (FBS) as previously described. 16 RASMCs were growth-arrested at Ϸ40% confluence using insulin-free, serumfree media. Cells were treated either with vehicle, PDGF-BB (30 ng/mL, Upstate), PDGF-BBϩCsA (3 mol/L, Sigma-Aldrich), or PDGF-BB ϩ A-285222 (10 mol/L, Abbott Laboratories). Cells treated with either CsA or A-285222 were pretreated with drug alone for 30 minutes before PDGF-BB stimulation.
Affymetrix Rat Expression Arrays and Analysis
RASMCs were growth arrested for 48 hours before PDGF-BB treatment both in the presence and absence of Cn/NFAT inhibitors, as described above. Total RNA was harvested at 3 hours posttreatment for each of the conditions (nϭ2 arrays per condition) using an RNeasy Mini Kit spin column (Qiagen). Total RNA was prepared according to manufacturer specifications (Affymetrix Rat Expression Array 230 2.0) at the University of Virginia GeneChip/Microarray Biostatistics Core (GSE19106). Arrays were analyzed as previously described. 13
Tissue Panel/Expression Analysis of Candidate NFAT Targets
Total RNA was harvested from tissues/cells according to kit specifications (Qiagen). cDNA was synthesized using the iScript cDNA Synthesis Kit (BioRad), and traditional reverse-transcription polymerase chain reaction (RT-PCR) was performed using Taq (Qiagen). Amplicon products were run on a 1% agarose/tris-acetate EDTA gel for imaging. Gene-specific RT-PCR primers were designed using Primer3 (Massachusetts Institute of Technology), and gene sequences were found for each primer product for validation (Supplemental Table I ).
Quantitative RT-PCR
Total RNA and cDNA were prepared from RASMCs as described above. Quantitative RT-PCR analysis (iCycler, BioRad) was performed using SYBR Green, as previously described. 13 Quantitative RT-PCRs on genes of interest were run in biological duplicates (triplicates for tϭ3 hours), and RNA abundance was normalized to 18S rRNA.
PROCR Promoter Construct Generation
The pGL3-PROCR-wild-type (WT)-luc plasmid construct contains 723 base pairs of the rat PROCR promoter (Ϫ701 to ϩ22). To make this construct, 908 base pairs of the WT PROCR promoter was originally amplified from rat normal liver genomic DNA (BioChain Institute) using the PROCR-8F (5Ј-GTGCACTTGTCCTCACAGCA) and PROCR-9R (5Ј-AAGCTTGAGGGAAGGGTGGAAAGAGA) primers. This amplicon was cloned into the pCR-XL-TOPO vector. A site-directed mutagenesis of the conserved NFAT binding motif (GGAAA3 TTAAA) was performed on the generated pCR-XL-TOPO-PROCR-WT plasmid using customized primers containing the desired mutation (Agilent Technologies). PROCR-9R contains a Hin-dIII linker at the 5Ј tail to facilitate subcloning. The rat PROCR promoter contains a SacI site at the Ϫ701 position. HindIII/SacI restriction digestion released a promoter fragment that was subcloned into the pGL3 vector (Promega). The pGL3-PROCR-MUT-luc plasmid was hence generated in parallel with the pGL3-PROCR-WT-luc plasmid. Sequence fidelity was confirmed by sequencing with RVprimer3 and RVprimer4 (Promega) (Supplemental Figure II ).
PROCR-Luciferase Activity Measurements
Cells were transfected with the PROCR-WT-luc (or PROCR-MUTluc) promoter construct 24 hours before treatment using FuGENE6 (Roche). Cells were harvested at designated time points by direct addition of 1 ϫ Passive Lysis Buffer (Promega). Luciferase activity was measured on an Omega FLUOstar plate reader (BMG Labtech), and fluorescence units were normalized to total protein.
Adenoviral Infection (Ad-CMV-Green Fluorescent Protein, Ad-VIVIT-Green Fluorescent Protein)
RASMCs were plated as previously described and growth arrested for 72 hours. Cells were transfected with either an empty green fluorescent protein vector (Viraquest) or a green fluorescent proteinlabeled, VIVIT-expressing adenovirus (courtesy of TE Harris, Department of Pharmacology, University of Virginia). RASMCs were infected with the appropriate adenovirus 24 hours before PDGF-BB or 10% FBS stimulation. Total cell number in a representative well was determined in order to infect cells at a consistent multiplicity of infection of 400 pfu/cell. Cells were treated with the appropriate phenotypic modulatory stimuli for the indicated time durations and harvested accordingly.
PROCR Western Blot
Protein lysates were collected by direct addition of a 2 ϫ Laemmli buffer solution. Equal protein volumes were loaded on a 10% SDS-PAGE gel and transferred to nitrocellulose membranes for protein quantification via Odyssey infrared imaging (LI-COR). Membranes were blocked in an Odyssey/PBS (1:1) blocking solution for at least 1 hour. Primary antibodies were diluted in an Odyssey/ PBS (1:1) blockingϩ0.1% Tween-20 solution, and membranes were allowed to incubate at 4°C overnight (anti-PROCR 1:200, Santa Cruz Biotechnology; anti-␤-tubulin 1:1000, Cell Signaling Technology). Fluorescently labeled secondary antibodies were used to detect protein signals on the Odyssey system (IRDye Secondary Antibodies).
PROCR Immunofluorescence
RASMCs were plated in chamber slides, as previously described, and treated with the indicated conditions. Cells were fixed in a 4% paraformaldehyde/PBS solution 6 hours poststimulation. Cells were permeabilized using a 0.02% Triton-X-100 solution and blocked in 0.1% BSA/PBS for at least 1 hour. Primary antibodies were diluted in 0.1% BSA/PBS (anti-PROCR 1:200, Santa Cruz Biotechnology), and cells were allowed to incubate at room temperature for at least 1.5 hours. Fluorescently labeled secondary antibodies were used to detect cytosolic PROCR, and DAPI stain was subsequently added (ProLong Gold, Invitrogen). Images were taken using a confocal microscope (Olympus).
PROCR Immunohistochemistry
The balloon-injury model was performed on rat carotid arteries, as previously described. 17 Both the injured carotid arteries and contralateral control arteries were harvested 7, 14, and 21 days postinjury. Paraffin-embedded sections underwent microwave antigen retrieval and were incubated with the PROCR antibody, as previously described. 18
Results
Whole-Genome Expression Analyses Identify Candidate Cn/NFAT-Dependent Genes
The overall objective of this study was to identify and validate novel Cn/NFAT-dependent genes involved in vascular SMC phenotypic modulation. A commonly used in vitro model of SMC phenotypic modulation involves stimulation of SMC monoculture with platelet-derived growth factor BB (PDGF-BB). 19, 20 We previously reported that NFATc transcriptional activity is rapid and transient in response to either PDGF-BB or serum stimulation in RASMCs. 13 In this study, we used a combination of pharmacological Cn/NFAT inhibitors and whole-genome expression arrays to identify candidate NFAT target genes. RNA for microarray analysis was isolated from SMCs pretreated with CsA or A-285222 for 30 minutes before 3 hours of PDGF-BB stimulation. Differentially upregulated genes were first identified in the PDGF-BB-treated array by comparing expression values with those in the vehicle-treated array. Differentially upregulated genes exhibited at least a 1.5-fold induction and a probability value Ͻ0.1 (Supplemental Figure IIIA, x) . Second, CsA-or A-285222-treated arrays were independently analyzed to identify genes that were decreased in expression relative to the PDGF-BB-treated array (Supplemental Figure IIIA , y). Differentially downregulated genes were identified in both CsA-and A-285222-treated arrays and subsequently merged to uncover genes whose PDGF-BB-mediated induction was sensitive to both CsA and A-285222 treatment (Supplemental Figure IIIB, z) . Genes were ranked by percentage reduction in expression as a result of each respective inhibitor (Table) . The 20 most sensitive genes were then subjected to rigorous follow-up validation.
Expression Analysis of Candidate NFAT-Regulated Genes in Rat Tissues and Cells
Although the NFAT transcription factor was originally described in T cells, NFAT signaling has been shown to exist in almost every cell type. We therefore examined mRNA expression levels of the 20 NFAT target gene candidates in a panel of normal rat tissues and rat vascular cell lines ( Figure  1 ). Most genes were expressed in 3 different blood vessels (carotid artery, abdominal aorta, thoracic aorta), aortic endothelial cells (ECs), and aortic SMCs. Some genes, such as DSCR1, DUSP1, and PDLIM5, were expressed at higher levels in blood vessels than in visceral smooth muscle. Originally described in ECs, 21 PROCR was identified in the array as a PDGF-BB-regulated gene in SMCs, but as shown here, it is highly expressed in ECs and barely detectable in quiescent SMCs.
PROCR Transcriptional Activity Is Dependent on Cn/NFAT Signaling
The top 20 candidate NFAT target genes underwent 2 different follow-up tests for Cn/NFAT dependence. First, Cn/NFAT dependence was investigated using CsA or A-285222 at 10 time points across 24 hours to visualize the expression profile of each gene. A second method of validation involved use of an adenovirus expressing the VIVIT peptide, an inhibitor of NFAT signaling. Endogenous NFAT activation requires binding of Cn to a conserved NFAT regulatory domain containing the PxIxIT consensus sequence. 22, 23 The VIVIT peptide has a higher affinity for the regulatory domain compared with Cn, thereby impairing NFAT activation without obstruction of other Cn-dependent downstream activity. 24 Experiments using the VIVIT peptide were completed only for the first 3 hours given that the identified genes by whole-genome expression analyses were upregulated within 3 hours of PDGF-BB stimulation.
We recently identified DSCR1 as a novel Cn/NFATdependent mediator of vascular SMC phenotypic modulation, 13 and it thus served as a positive control in this study (Table) . Validation experiments in our previous approach used identical pharmacological inhibitors. DSCR1 expression in response to PDGF-BB was rapid and transient, peaking at 1 hour (Ϸ28-fold), with significant inhibition in the presence of either CsA or A-285222 ( Figure 2A , taken from 13 ). Likewise, DSCR1 expression was upregulated at 0.5, 1, and 3 hours following PDGF-BB stimulation, with significant attenuation in the presence of the VIVIT peptide ( Figure 2B ). Use of the VIVIT peptide in this study further demonstrated the NFAT-dependent property of DSCR1 expression in vascular SMCs. The expression pattern of DSCR1 at the 3-hour time point in Figure 2B was similar to but not as robust as the 1-hour response, perhaps because of the transient nature of DSCR1 expression. Adenoviral-treated cells also appeared to exhibit an attenuation in peak mRNA fold change values ( Figure 2B , 2D, and 2F compared with Figure 2A , 2C, and 2E), an experimental artifact that has been observed in previously published studies. DSCR1 and PROCR, however, maintained NFAT dependence as trends were sustained regardless of the inhibitor used.
The 20 NFAT target genes presented in the Table were subject to both validation procedures, including use of the VIVIT peptide (Supplemental Figure IV) . PROCR mRNA was upregulated Ϸ25-fold as early as 1 hour following PDGF-BB stimulation and attenuated by treatment with either CsA or A-285222 ( Figure 2C ). Use of the VIVIT peptide together with PDGF-BB significantly reduced PROCR mRNA expression, emphasizing the NFATdependence of PROCR gene expression ( Figure 2D ). On the other hand, Ϸ35% of the 20 candidate target genes did not meet the follow-up criteria for Cn/NFAT dependence. For example, RAPGEF2 was identified by array analyses to be Cn/NFAT dependent (Table) , but in vitro validation showed that PDGF-BB-induced RAPGEF2 expression was not dependent on Cn/NFAT activity ( Figure 2E ). In addition, RAPGEF2 mRNA expression did not appear to change in response to the VIVIT peptide ( Figure 2F ), indicating Cn/ NFAT signaling was not required for RAPGEF2 expression in vascular SMCs. Despite the presence of false positives in our genomics approach, several observations are of interest. For example, many of the candidate NFAT targets exhibited PDGF-BB-induced gene expression at time points earlier than 3 hours of treatment (Supplemental Figure IV) . Furthermore, several of these target genes demonstrated significant attenuation in PDGF-BB-induced signal with the VIVIT peptide at the 1-hour time point, suggesting that peak NFAT transcriptional activity occurred earlier than predicted. Importantly, microarray-derived biological responses undoubtedly require subsequent in vitro validation, given the relative abundance of false-positives identified in our follow-up studies.
In this study, we chose to follow up on the PROCR gene because (1) PROCR was only recently identified as being expressed in vascular SMCs, 15 and (2) transcription factors that regulate PROCR expression have not be clearly identified in any cell type.
PROCR Promoter Activation Is Cn/NFAT Dependent
The PROCR promoter contains 1 NFAT binding site 8 base pairs upstream of the transcriptional start site. Bioinformatic analyses showed that this particular NFAT site is conserved across 8 species, ranging from human to opossum ( Figure  3A) . To measure PROCR promoter activity, 723 base pairs of the rat PROCR promoter were cloned upstream of the firefly luciferase gene in a plasmid vector (PROCR-WT-luc). SMCs were transfected with the PROCR-WT-luc plasmid construct and subsequently treated with PDGF-BB. PROCR promoter activity increased Ϸ7-fold in response to 6 hours of PDGF-BB treatment and was significantly reduced when PDGF-BB-induced changes in gene expression are indicated by fold change (PDGF-BB compared with vehicle). Differentially upregulated genes exhibit at least a 1.5-fold induction and a P value of Ͻ0.1. Reduction in differential gene expression as a result of cyclosporin A or A-285222 treatment is denoted by percentage decrease for each inhibitor (nϭ2 arrays per condition). PDGF indicates platelet-derived growth factor; NFAT, nuclear factor of activated T cells. treated in the presence of either CsA or A-285222 ( Figure  3B ). We also tested PROCR-WT-luc activity in the presence of the VIVIT peptide. PROCR promoter activity was completely blocked following expression of the VIVIT peptide ( Figure 3C ). VIVIT expression also lowered basal PROCR-WT-luc activity. A point mutation was introduced into the NFAT binding site (GGAAA3 TTAAA, Supplemental Figure II) to determine whether the identified NFAT motif is necessary for optimal PROCR promoter activation. Mutation of the NFAT site resulted in significant reduction of PDGF-BB-induced PROCR promoter activity, suggesting that NFAT is necessary for PROCR expression ( Figure 3D ). The presence of Ϸ50% activity despite the introduced mutation suggests that other transcription factors (ie, Specificity protein 1 [Sp1]; refer to the Discussion) may be involved in activation of PROCR expression in smooth muscle. SMCs were also treated with PDGF-BB or 10% FBS over a span of 24 hours to compare the effects of differing phenotypic modulatory stimuli on PROCR promoter activity. Interestingly, the PROCR promoter was activated relatively early in response to PDGF-BB stimulation, peaking at 3 hours (Ϸ2.1fold), whereas stimulation with 10% FBS resulted in a delayed response, with peak promoter activity occurring at 12 hours ( Figure 3E ). These findings suggest that the window of PROCR promoter activation is differentially regulated by different stimuli and signaling pathways.
PROCR Protein Expression Is Cn/NFAT Dependent
PROCR protein expression was measured to test NFAT dependence at the translational level. PROCR protein levels increased Ϸ2.5-fold in response to 6 hours of PDGF-BB treatment when normalized to vehicle-treated samples. PROCR protein expression was significantly attenuated following treatment with either CsA or A-285222 ( Figure 4A ). Treatment with 10% FBS did not show a pronounced increase in PROCR protein expression. It is likely that this observation is a result of differing signaling mechanisms that may be involved in PROCR activation, where PDGF-BB stimulation results in a relatively quicker response compared with 10% FBS treatment. This trend was also observed at the promoter level in Figure 3E .
We also investigated PROCR localization in response to PDGF-BB stimulation by immunofluorescence microscopy. As shown in Figure 4B , PROCR was localized near the periphery of the nucleus in untreated SMCs, similar to intracellular PROCR staining in vascular ECs. 25 PDGF-BB stimulation for 6 hours induced a punctate redistribution of PROCR from the perinuclear region toward the cytoplasm. Pretreatment with CsA inhibited the PDGF-BB-induced cytoplasmic redistribution, as evidenced by restoration of the perinuclear pattern seen with vehicle controls. Although our immunofluorescence may not visually reflect the protein changes seen via Western blot, it is possible this discrepancy is due to the fact that Figure 3B reflects a single plane of the z-axis.
PROCR Expression Is Upregulated in Response to Acute Carotid Artery Balloon Injury
In vitro experimentation clearly demonstrated the Cn/ NFAT-dependent regulation of PROCR at the promoter, transcriptional, and translational level. Previous studies demonstrate that Cn/NFAT signaling modulates injuryinduced neointima formation. 5 Immunohistological staining of PROCR was performed on balloon-injured rat carotid arteries to determine how PROCR expression changed as a function of time postinjury, as previously described 26, 27 (Figure 5 ). Both injured and contralateral control arteries were harvested at 7, 14, and 21 days postinjury. Positive PROCR staining in the media of contralateral arteries supported the recent finding that vascular SMCs express PROCR, 15 although at a relatively low level. In balloon-injured arteries, staining patterns indicated that PROCR expression was upregulated with injury. Visual assessment of PROCR intensity suggested that PROCR induction occurred as early as 7 days postinjury and that PROCR continued to be highly expressed in neointimal SMCs thereafter ( Figure 5D-5F ). EC expression of PROCR could not be seen in the injured artery samples, as this procedure removes the endothelium at the time of injury. The contralateral control artery, however, exhibited endothelial staining, with maximal intensity occurring at 21 days postinjury. A cross-section of an apolipoprotein E Ϫ/Ϫ mouse aorta was also used as a positive control for endothelial PROCR expression in intact tissue (Supplemental Figure V) . Interestingly, the 21 days contralateral control exhibited increased PROCR expression in vascular SMCs relative to the 7 day control artery ( Figure 5C ). It is possible that balloon injury in the opposing carotid artery elevated blood thrombin levels as a result of vascular injury. Thrombin has also been shown to activate NFAT signaling 6, 28 and to induce PROCR promoter activity in vascular SMCs (Supplemental Figure VI ).
Discussion
In this study, we used whole-genome array analysis and pharmacological reagents to identify PROCR as a potential Cn/NFAT-dependent gene in vascular smooth muscle. We corroborate the only report to date that vascular SMCs do express the protein C receptor (PROCR). 15 More importantly, we validate our informatics approach and are the first to report Cn/NFAT signaling as a regulator of PROCR activation. We show PDGF-BB stimulation induced PROCR expression in a Cn/NFAT-dependent manner at both the transcriptional and translational levels. Mutation of a highly 13 ) and PROCR (C) mRNA expression was upregulated in response to platelet-derived growth factor-BB (PDGF-BB) stimulation (30 ng/mL). Transcriptional activation, however, was attenuated on treatment with either cyclosporin A (CsA) (3 mol/L) or A-285222 (10 mol/L). Similar results were seen with use of the VIVIT peptide; DSCR1 and PROCR expressions were inhibited at 0.5, 1, and 3 hours (B) and 1 and 3 hours (D) on treatment, respectively. PDGF-BB-induced RAPGEF2 gene activation did not appear to be Cn/NFAT dependent (E and F). Representative graphs are shown for A, C, and E. Target mRNA levels are normalized to the 18S housekeeping gene. Treatment conditions are normalized to the respective vehicle conditions. nՆ3, *PϽ0.05, ***PϽ0.001.
conserved NFAT binding motif significantly attenuated PROCR promoter activation, supporting the NFATdependent property of PROCR activity. In addition, PROCR expression is upregulated in vivo as a result of acute vascular injury, highlighting the potential role of PROCR in vessel restenosis.
Until the recent detection of PROCR in vascular SMCs, PROCR was believed to be expressed predominantly in ECs. Studies to date on PROCR transcription focus primarily on the mechanisms of cell specificity during developmental cell differentiation rather than identification of transcription factor modules operating at the PROCR promoter. One group identified multiple Sp1 consensus sequences at the PROCR promoter. Electrophoretic mobility shift assays and promoter reporter assays in ECs have demonstrated binding of Sp1 to the PROCR promoter and direct contribution to reporter gene expression, respectively. 29 However, no single Sp1 binding site was found to be critical for PROCR promoter activity, as site mutations do not result in significant loss of reporter gene activity. 29 Interestingly, PDGF-BB stimulation increases Sp1 expression in cultured vascular SMCs, 30 and balloon angioplasty induces neointimal Sp1 expression in vivo. 31, 32 Furthermore, Sp1 has been shown to suppress classic SMC contractile genes, namely SM22␣ and SMMHC. 30 Sp1 and NFAT may both be necessary for optimal PROCR expression, as cross-talk between the Sp1 and NFAT proteins has been observed in activation of other genes. 33, 34 With regard to biological function, PROCR has been studied almost exclusively in the context of endothelial barrier protection and blood coagulation. Although the functional role of PROCR in vascular SMCs is virtually unknown, research in endothelial biology provides several clues as to what may be occurring in vascular SMCs. The discovery of PROCR in ECs uncovered a novel plasma membrane receptor critical for the protective qualities of activated protein C (APC) in a variety of diseases, including tumor metastasis, 35 myocardial infarction/reperfusion injury, 36 and severe sepsis. 37 In 2000, a group using a primate model of Escherichia coli-mediated septic shock found that binding of APC to PROCR was vital in the host defense against E. coli; inhibition of APC-PROCR binding altered a normally tolerable response to E. coli into a lethal response. 38 The mechanism of protection against E. coli-induced sepsis by APC, however, was yet to be determined. In 2002, Riewald et al demonstrated that APC-bound PROCR activated downstream PAR-1 signaling in ECs, providing a mechanism behind PROCR-dependent APC-mediated sepsis protection. 39 In support of this finding, an in vivo study demonstrated that APC reduces vascular permeability through PAR-1 in mice. 40 PAR-1 is better known as a thrombin receptor whose interaction with thrombin results in endothelial barrier dysfunction. 41 The identification of PAR-1 activation via APC-bound PROCR thus became a paradoxical observation: how does PAR-1, a prototypical thrombin receptor, also mediate the endothelial barrier protective effects of APC? Intriguingly, vascular SMCs have also been shown to not only express functional PROCR but also bind APC for downstream PAR-1 activation and SMC proliferation, suggesting that this signaling axis is implicated in SMC phenotypic modulation. 15 A recent study found that APC-mediated endothelial barrier protection occurs through cross-talk of PAR-1 and the sphingosine-1-phosphate (S1P) signaling pathway. Barrier protection by APC occurs through PAR-1-dependent upregulation of sphingosine kinase 1 (a kinase required for generation of S1P) and binding of de novo S1P to the S1P1 receptor in ECs. 42, 43 S1P, a bioactive phospholipid, has been demonstrated to reorganize the endothelial cytoskeleton and increase cellular adhesion through S1P1, resulting in decreased endothelial permeability. 44 We have shown that vascular SMCs differentially express S1P1, S1P2, and S1P3 in response to acute vascular injury. 17 In addition, unpublished data from our group indicate that PDGF-BB-stimulated SMCs induce sphingosine kinase 1 expression in vitro, whereas in vivo, sphingosine kinase 1 activity and S1P levels are increased as a result of acute vascular injury (unpublished). Upregulation of PROCR (herein), PAR-1, 45 S1P1, 17 and sphingosine kinase 1 in response to vascular injury suggests that APC-PROCRdependent PAR-1 signaling could be a major contributor to the S1P levels found in atherosclerosis and in-stent restenosis. 46 S1P may also exert its effects through S1P1 in vascular SMCs but exhibit biological outcomes different from those observed in ECs. APC-mediated PAR-1 signaling, although protective in ECs, may promote SMC phenotypic modulation for inward vessel remodeling. Cross-talk between Cn/NFAT, S1P, and PAR1 signaling pathways also leads us toward an interactive, coordinated, and more robust model of Cn/NFAT signaling in SMCs.
APC-PROCR-dependent PAR-1 activation has also been shown to increase monocyte chemoattractant protein-1 (MCP-1/CCL2) expression in ECs. 39 MCP-1 is a major regulatory chemokine secreted by several cell types, including vascular SMCs, and is known to mediate monocyte/macrophage migration and infiltration. 47, 48 Hence, MCP-1 is a major determinant in atherosclerotic plaque formation, as evidenced by 2 well-known atherosclerotic mouse models, low-density lipoprotein receptor Ϫ/Ϫ and apolipoprotein E Ϫ/Ϫ mice. 49, 50 Given the similarities in signaling mechanisms between ECs and vascular SMCs thus far, it is possible that upregulation of APC-PROCR-dependent PAR-1 activation will also lead to upregulation of MCP-1 in vascular SMCs. PROCR has also been found to exist in a soluble form with full ligand-binding capability. 51 Interestingly, soluble PROCR can bind to activated neutrophils through proteinase-3 and partial dependence on neutrophil-expressed Mac-1 integrin protein. 52 This discovery suggests that PROCR is involved, not only as a signaling factor/receptor but also as an adhesion molecule. Furthermore, inhibition of APC binding to PROCR is correlated with intense neutrophil influx into tissues, 38 suggesting that PROCR is somehow involved in leukocyte trafficking. Monocyte/macrophage infiltration into the vessel medial layer is a characteristic event of atherosclerotic plaque development, where Mac-1 is often used as a marker for macrophage involvement. 53, 54 The proposed increase in MCP-1 generation together with increased PROCR expression could be a synergistic attempt by vascular SMCs for monocyte recruitment. Further experimentation, however, is critical in addressing these hypotheses and in elucidating the function of PROCR in vascular SMCs.
In summary, the data presented herein demonstrate the value of a high-throughput, whole-genome approach in identification of novel transcriptional targets and, importantly, follow-up in vitro validation studies. Above all, we show for the first time that PROCR expression in vascular SMCs is dependent on Cn/NFAT signaling and upregulated in response to acute vascular injury. This is the first study to validate a transcription factor that regulates PROCR in any cell type. Although our current understanding of PROCR function in vascular SMCs is truly in its infancy, it is evident that PROCR may have significant implications in SMC phenotypic modulation and vascular disease.
